期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

奥氮平对青少年精神分裂症患者认知损害的疗效观察 被引量：4

原文传递
导出
摘要 目的探讨奥氮平对青少年精神分裂症患者认知损害的治疗作用。方法将60例青少年精神分裂症患者按数字表法随机分为两组，每组30例，观察组使用奥氮平治疗，对照组使用氟哌啶醇治疗，治疗前后使用阳性与阴性症状量表（PANSS）、威斯星卡片分类测试（WCST）及精神分裂症认知功能成套测验共识版（MCCB）进行评估。结果治疗8周后观察组PANSS、WCST及MCCB评分较治疗前有明显改善（P〈0．01或P〈0．05），且较对照组改善明显（P〈0．01或P〈0．05）。结论奥氮平能有效改善青少年精神分裂症的认知功能损害。
作者 陈兴阳 齐钢桥 许蔚倩 齐文耀
机构地区 台州市第二人民医院精神科
出处 《中国基层医药》 CAS 2013年第22期3453-3454,共2页 Chinese Journal of Primary Medicine and Pharmacy
关键词 精神分裂症 认知损害 奥氮平 氟哌啶醇 青少年
分类号 R749.3 [医药卫生—神经病学与精神病学]
  • 相关文献

参考文献16

  • 1Harvey PD, Green MF, Bowie C, et al. The dimensions of clinical and cognitive change in schizophrenia:evidence for independence of improvements. Psychopharmacology ( Berl ), 2006, 187 ( 3 ) : 356-363.
  • 2Green MF, Nuechtedein KH, Gold JM,et al. Approaching a con- sensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry,2004,56 ( 5 ) :301-307.
  • 3Green MF, Kern RS, Braff DL, et al. Neurocognitive deficits and functional outcome in sehizophrenia:are we measuring the "fight stuff". Sehizophr Bu11,2000,26 ( 1 ) : 119-136.
  • 4Green MF, Nuechterlein KH. Should schizophrenia be treated as a neurocognitive disorder?. Schizophr Bull, 1999,25 ( 2 ) : 309 -319.
  • 5潘丽妹,李梁,潘江艳,林国华.非典型抗精神病药物与精神分裂症认知功能[J].右江民族医学院学报,2007,29(6):999-1002. 被引量：4
  • 6谭云龙,邹义壮,屈英,郭蓄芳.威斯康星卡片分类测验常用指标的稳定性分析[J].中国心理卫生杂志,2002,16(12):831-833. 被引量：89
  • 7邹义壮,崔界峰,王健,陈楠,谭淑平,张东,徐泽,宋少刚,王云辉,李玥,高文静,段京辉.精神分裂症认知功能成套测验中文版临床信度及效度的研究[J].中华精神科杂志,2009,42(1):29-33. 被引量：181
  • 8Medalia A, Lim R. Treatment of cognitive dysfunction in psychiat- ric disorders. J Psychiatr Pract,2004,10( 1 ) : 17-25.
  • 9牛雅娟,吴承京,吉中孚.精神分裂症患者认知功能与精神症状相关性研究[J].临床精神医学杂志,2007,17(2):110-111. 被引量：28
  • 10Harvey PD, Green MF, Keefe RS, et al. Cognitive functioning in schizophrenia: a cohsensus statement on its role in the definition and evaluation of effective treatments for the illness. Clin Psychia- try,2004,65 ( 3 ) :361-372.

二级参考文献65

  • 1胡一文,王高华,王惠玲,舒畅.首发精神分裂症患者认知功能与阴性症状的相关性[J].中国临床康复,2005,9(12):52-53. 被引量：16
  • 2Yamashita C, Mizuno M, Nemoto T, et al. Social cognitive problem-solving in schizophrenia: associations with fluency and verbal memory. Psychiatry Res, 2005, 134 : 123-129.
  • 3Penades R, Boget T, Catalon R, et al. Cognitive mechanisms, psychosocial functioning, and neurocognitive rehabilitation in schizophrenia. Schizophr Res, 2003,63:219-227.
  • 4Marder SR, Fenton W. Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia. Schizophr Res, 2004, 72:5-9.
  • 5Kern RS, Green MF, Nuechterlein KH, et al. NIMH-MATRICS survey on assessment of neurocognition in schizophrenia. Schizophr Res, 2004,72:11-19.
  • 6Green MF, Nueehterlein KH. The MATRICS initiative: developing a consensus cognitive battery for clinical trials. Schizophr Res, 2004, 72 : 1-3.
  • 7Green MF, Nuechterlein KH, Gold JM, et al. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry, 2004,56:301-307.
  • 8Nuechterlein KH, Barch DM, Gold JM, et al. Identification of separable cognitive factors in schizophrenia. Schizophr Res, 2004, 72:29-39.
  • 9Nuechterlein KH, Green MF, Kern RS, et al. The MATRICS Consensus Cognitive Battery, part 1 : test selection, reliability, and validity. Am J Psychiatry, 2008,165:203-313.
  • 10Kern RS, Nuechterlein KH, Green MF, et al. The MATRICS Consensus Cognitive Battery, part 2 : eo-norming and standardization. Am J Psychiatry, 2008,165:214-220.

共引文献311

同被引文献36

  • 1胡华,邓伟,杨辉,刘玉.奥氮平与氟哌啶醇治疗老年性谵妄的随机对照观察(英文)[J].中国临床康复,2006,10(42):188-190. 被引量：13
  • 2Practice guideline for the treatment of patients with delirium.American Psychiatric Association[J].Am J Psychiatry,1999,156(5Suppl):1-20.
  • 3Morandi A,Jackson JC.Delirium in the intensive care unit:a review[J].Neurol Clin,2011,29:749-763.
  • 4McCusker J,Cole MG,Voyer P,et al.Prevalence and incidence of delirium in long-term care[J].Int J Geriatr Psychiatry,2011,26(11):1 152-1 161.
  • 5Wang EH,Mabasa VH,Loh GW,et al.Haloperidol dosing strategies in the treatment of delirium in the critically ill[J].Neurocrit Care,2012,16(1):170-183.
  • 6Pelland C,Trudel JF.Atypical antipsychotic efficacy and safety in managing delirium:a systematic review and critical analysis[J].Psychol Neuropsychiatr Vieil,2009,7(2):109-119.
  • 7Yoon HJ,Park KM,Choi WJ,et al.Efficacy and safety of haloperidol versus atypical antipsychotic medications in the treatment of delirium[J].BMC Psychiatry,2013,13:240.
  • 8Grover S,Kumar V,Chakrabarti S.Comparative efficacy study of haloperidol,olanzapine and risperidone in delirium[J].J Psychosom Res,2011,71(4):277-281.
  • 9世界卫生组织.国际疾病与相关健康问题分类精神障碍分册.第10版.北京:人民卫生出版社,1993:59-182.
  • 10Shan D, Lucas EK, Drummond JB, et al. Abnormal expression of glutamate transporters in temporal lobe areas in elderly pa- tients with schizophrenia. Schizophr Res. 2013; 144(1-3): 1-8.

引证文献4

二级引证文献25

中国基层医药
2013年 第22期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部